Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)

NCT04315324 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT04315324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04315324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 8, 2021
Completion date
August 1, 2028
Enrollment
67 (estimated)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent t acute lymphoblastic leukemia, refractory t acute lymphoblastic leukemia, refractory t lymphoblastic lymphoma, t lymphoblastic lymphoma